Gilead Sciences (GILD) has agreed to pay $202 million in the settlement of a civil fraud lawsuit accusing it of paying kickbacks to healthcare practitioners to promote its HIV treatment drugs, the US Attorney for the Southern District of New York said in a Tuesday statement.
The illegal kickbacks caused false claims for Gilead's HIV drugs to be paid by federal healthcare programs, in violation of the False Claims Act, according to the statement.
Under the settlement, Gilead agreed to pay a total sum of $202 million, of which around $176.9 million will be paid to the US and the remainder will be paid to various states. As part of the settlement, the company also made extensive factual admissions regarding its conduct, the statement said.
The settlement was approved Monday by US District Judge Paul Engelmayer.
Gilead did not immediately reply to a request for comment from MT Newswires.
Price: 106.17, Change: -0.17, Percent Change: -0.16
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。